GLPwatch
Safety and Efficacy of Liraglutide in Parkinson's Disease
NCT02953665 · Completed
Last updated 2026-05-28This clinical trial tested the safety and effects of the drug liraglutide in adults with Parkinson's disease.
Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 63 people
Who can join Ages 25–85 · all sexes
Timeline Started 2017-04 · est. completion 2022-08
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT02953665 ↗
Description as written by the study sponsor.
The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).
Treatments tested
- Liraglutide also known as Victoza, Saxenda Drug
Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
- Placebo Drug
Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
| Main thing measured | Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period |
|---|---|
| Sponsor | Cedars-Sinai Medical Center |
| Conditions studied | Parkinson Disease |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02953665 ↗